Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
66.39
-2.81 (-4.07%)
Streaming Delayed Price
Updated: 12:54 PM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
↗
November 01, 2024
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
↗
November 01, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 31, 2024
Via
Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
↗
October 31, 2024
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.
Via
Chartmill
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
↗
October 30, 2024
Via
Benzinga
Unveiling 12 Analyst Insights On Halozyme Therapeutics
↗
October 25, 2024
Via
Benzinga
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
↗
October 22, 2024
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.
Via
Chartmill
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
↗
October 11, 2024
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Via
Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
↗
October 10, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts
↗
October 04, 2024
Via
Benzinga
NASDAQ:HALO is showing good growth, while it is not too expensive.
↗
September 19, 2024
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.
Via
Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
September 19, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
↗
September 13, 2024
Via
Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
↗
August 29, 2024
NASDAQ:HALO is showing good growth, while it is not too expensive.
Via
Chartmill
Top 2 Health Care Stocks That May Plunge In August
↗
August 26, 2024
Via
Benzinga
How Is The Market Feeling About Halozyme Therapeutics?
↗
August 20, 2024
Via
Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
↗
September 13, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
↗
September 13, 2024
Via
Benzinga
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
August 28, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying.
Via
Chartmill
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
↗
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
↗
August 08, 2024
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.
Via
Chartmill
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
↗
August 01, 2024
Via
Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
↗
August 01, 2024
Via
Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
↗
August 08, 2024
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 06, 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
↗
August 06, 2024
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Via
Investor's Business Daily
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
↗
August 06, 2024
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
Via
Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
↗
August 05, 2024
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
↗
August 04, 2024
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
